Ингибирование теломеразы человека (1105569), страница 19
Текст из файла (страница 19)
P. 605-614.[153] Iakovidis I.; Delimaris I., Piperakis S. M. Copper and its complexes in131[154][155][156][157][158][159][160][161][162][163][164][165][166]medicine: a biochemical approach. // Mol. Biol. Int. 2011. P. 1-13.Cristofari G., Lingner J.
Telomere length homeostasis requires that telomeraselevels are limiting. // EMBO J. 2006. V. 25. P. 565-574.Suzuki M., Kasai K., Saeki Y. Plasmid DNA sequences present inconventional herpes simplex virus amplicon vectors cause rapid transgenesilencing by forming inactive chromatin. // J Virol. 2006. V. 80. P. 3293-300.Backliwal G., Hildinger M., Chenuet S., Dejesus M., Wurm F.M.Coexpression of acidic fibroblast growth factor enhances specific productivityand antibody titers in transiently transfected HEK293 cells.
// N Biotechnol.2008. V. 25. P. 162-166.Ali S.H., DeCaprio J.A. Cellular transformation by SV40 large T antigen:interaction with host proteins. // Semin Cancer Biol. 2001. V. 11. P. 15-23.Durocher Y., Perret S., Kamen A. High-level and high-throughputrecombinant protein production by transient transfection of suspensiongrowing human 293-EBNA1 cells.
// Nucleic Acids Res. 2002. V. 30. P. e9.Van Craenenbroeck K., Vanhoenacker P., Haegeman G. Episomal vectors forgene expression in mammalian cells. // Eur J Biochem. 2000. V. 267. P. 56655678.Koons M.D., Van Scoy S., Hearing J. The replicator of the Epstein-Barr viruslatent cycle origin of DNA replication, oriP, is composed of multiplefunctional elements. // J Virol. 2000.
V. 75. P. 10582-10592.Darquet A.M., Cameron B., Wils P., Scherman D., Crouzet J. A new DNAvehicle for nonviral gene delivery: supercoiled minicircle. // Gene Ther. 1997.V. 14. P. 1341-1349.Yates J.L., Camiolo S.M., Bashaw J.M. The Minimal Replicator of EpsteinBarr Virus oriP. // Journal Of Virology. 2000.
V. 74. P. 4512–4522.Weber K., Bartsch U., Stocking C., Fehse B. A multicolor panel of novellentiviral "gene ontology" (LeGO) vectors for functional gene analysis. // MolTher. 2008. V. 16. P. 689-706.Chen J.L., Greider C.W. Functional analysis of the pseudoknot structure inhuman telomerase RNA. // Proc Natl Acad Sci U S A. 2005. V. 102. P. 80808085.Ueda C.T., Roberts R.W. Analysis of a long-range interaction betweenconserved domains of human telomerase RNA.
// RNA. 2014. V. 10. P. 139147.Chen Z., Monia B.P., Corey D.R. Telomerase inhibition, telomere shortening,and decreased cell proliferation by cell permeable 2'-O-methoxyethyloligonucleotides. // J Med Chem. 2002. V. 45. P. 5423-5425.132[167] Золотов. Ю.А. Основы аналитической химии. – М.: Высшая школа, 2000.[168] Templeton N.S.
Gene and Cell Therapy: Therapeutic Mechanisms andStrategies. // Taylor & Francis Group. 2009.[169] Varshney A., Ramakrishnan S.K., Sharma A., Santosh B., Bala J., YadavaP.K., Jaiswal R.K. Global expression profile of telomerase-associated genesin HeLa cells. // Gene. 2014. V. 547. P. 211-217.[170] Li S., Rosenberg J.E., Donjacour A.A., Botchkina I.L., Hom Y.K., CunhaG.R., Blackburn E.H. Rapid Inhibition of Cancer Cell Growth Induced byLentiviral Delivery and Expression of Mutant-Template Telomerase RNA andAnti-telomerase Short-Interfering RNA. // Cancer Res. 2004.
V. 64. P. 48334840.[171] Cotton M., Saltik M., Baker A. Transfection Complexes Generated withAdenovirus and Polyethylenimine-Condensed DNA. // Adenovirus Methodsand Protocols. 1999. V. 21. P. 295-307.[172] Yasuda K., Ogawa Y., Yamane I., Nishikawa M., Takakura Y. Macrophageactivation by a DNA/cationic liposome complex requires endosomalacidification and TLR9-dependent and -independent pathways. // J LeukocBiol.
2005. V. 77. P. 71-79.[173] Bradford M.M. A rapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding.//Anal Biochem. 1976. V. 72. P. 248-254.1336. ПриложениеПриложение 1BCDEF134GHIJLKMN135OQPRSTU*V136WXИнгибирование теломеразы модифицированными олигонуклеотидами вусловиях in vitro. (●) – Ингибирование теломеразы, олигонуклеотиды былидобавленывтеломеразнуюреакцию.(○)–ИнгибированиеПЦР,олигонуклеотиды были добавлены после теломеразной реакции и перед ПЦР.
A- c3G, B – Mc3M, C – Nmisc3J, D – c3N, E – c3J, F – Nc3J, G – N*c3J, H- Mc3N, I- compNc3compJ, J – Mc3, K - M*c3M, L – Mc3N*, M – M*c3N, N – MMc3, O –Nmisc3Jmis, P – c3MN, Q – Nc3M, R – Nc3Jmis, S – MNc3, T – MmisNmisc3, U –Jc3N, V – c3M, W – c3Mc3N, X – c3Mc3M.U*- для Jc3N было использовано 100 кратное разбавление.137Приложение 2ACEBDF138GIKHJL139MNOPQR140STUWVXИнгибирование теломеразы модифицированными олигонуклеотидами вусолвиях in vivo.
A - c3N, B – c3J, C – N3J, D – N*3J, E – Jc3N, F –compNc3compJ, G – M*c3N, H- Mc3N, I - Nmisc3Jmis, J – Mc3N*, K - Nc3M, L –MmisNmisc3, M – c3G, N – c3MN, O – Mc3M, P – MNc3, Q – M*c3M, R – MMc3,S – Nmisc3J, T – Nc3Jmis, U –c3M, V – Mc3, W- c3Mc3M, X – c3Mc3N141Приложение 3.142Ингибирование теломеразы низкомолекулярными веществами в усолвиях invitro. (●) – Ингибирование теломеразы, олигонуклеотиды были добавлены втеломеразную реакцию. (○) – Ингибирование ПЦР, олигонуклеотиды былидобавлены после теломеразной реакции и перед ПЦР..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
